HomeCompareINZY vs MO

INZY vs MO: Dividend Comparison 2026

INZY yields 50.00% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INZY wins by $313.9K in total portfolio value
10 years
INZY
INZY
● Live price
50.00%
Share price
$4.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.0K
Annual income
$79,849.97
Full INZY calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — INZY vs MO

📍 INZY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINZYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INZY + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INZY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INZY
Annual income on $10K today (after 15% tax)
$4,250.00/yr
After 10yr DRIP, annual income (after tax)
$67,872.47/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, INZY beats the other by $42,237.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INZY + MO for your $10,000?

INZY: 50%MO: 50%
100% MO50/50100% INZY
Portfolio after 10yr
$237.1K
Annual income
$55,004.56/yr
Blended yield
23.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

INZY
Analyst Ratings
6
Buy
3
Hold
Consensus: Buy
Price Target
$12.00
+200.0% upside vs current
Range: $4.00 — $16.00
Altman Z
-6.5
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INZY buys
0
MO buys
0
No recent congressional trades found for INZY or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINZYMO
Forward yield50.00%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$394.0K$80.1K
Annual income after 10y$79,849.97$30,159.17
Total dividends collected$314.4K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$12.00$61.25

Year-by-year: INZY vs MO ($10,000, DRIP)

YearINZY PortfolioINZY Income/yrMO PortfolioMO Income/yrGap
1← crossover$15,700$5,000.00$10,570$780.30+$5.1KINZY
2$24,135$7,336.45$11,381$1,032.90+$12.8KINZY
3$36,365$10,540.42$12,535$1,392.73+$23.8KINZY
4$53,753$14,842.48$14,193$1,920.91+$39.6KINZY
5$78,020$20,504.11$16,618$2,723.68+$61.4KINZY
6$111,295$27,813.68$20,263$3,993.80+$91.0KINZY
7$156,166$37,080.39$25,936$6,098.36+$130.2KINZY
8$215,724$48,626.29$35,166$9,775.01+$180.6KINZY
9$293,602$62,776.77$51,026$16,597.78+$242.6KINZY
10$394,004$79,849.97$80,113$30,159.17+$313.9KINZY

INZY vs MO: Complete Analysis 2026

INZYStock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Full INZY Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this INZY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INZY vs SCHDINZY vs JEPIINZY vs OINZY vs KOINZY vs MAININZY vs PMINZY vs BTIINZY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.